Original Research Article
Year: 2017 | Month: April | Volume: 7 | Issue: 4 | Pages: 210-216
Concurrent Derangement of Lipid Profile and Risk Evaluation of Cardiovascular Diseases in Hyperuricemic Patients
Dr Rashmi Rekha Phukan
MD Biochemistry, Assistant Professor, Department of Biochemistry, Sikkim Manipal Institute of Medical Sciences, Gangtok 737102, East Sikkim, Sikkim, India.
Background: The association of hyperuricemia and cardiovascular diseases is known for several years. However the exact role of uric acid in developing cardiovascular diseases is still not well established. Dyslipidemia is a well-known risk factor for development of cardiovascular diseases which often accompanies hyperuricemia.
Aim: aim of the study is to observe the association of dyslipidemia in hyperuricemic patients and to assess their risk of future cardiovascular diseases.
Materials and methods: The study is conducted retrospectively including 71 hyperuricemic patients and the data of lipid profile and its ratios were compared with 48 apparently healthy normouricemic controls.
Result: serum triglyceride (cases 179.732 ± 44.882, controls 167.937 ± 41.502), triglyceride/HDL ratio (cases 4.354 ±2.506; controls2.514±1.215), Total cholesterol/HDL ratio (cases 3.687± 1.066, controls 3.165±0.788), LDL/HDL ratio (cases 2.188 ± 0.811, controls; 1.835±0.708), were found to be elevated significantly in hyperuricemic patients. Total cholesterol, LDL was although higher in the patient group but was statistically non-significant. HDL cholesterol value in cases was lower as compared to the controls but was statistically not significant.
Conclusion: hyperuricemic patients are at a higher risk of developing future cardiovascular diseases not only because of hyperuricemia but also due to accompanying dyslipidemia. The frequent coexistence of dyslipidemia in hyperuricemic patients might have synergistic action along with uric acid in developing cardiovascular diseases in hyperuricemic patients. Follow up with lipid profile estimation and treatment with hypolipidemic drugs preferably targeting triglyceride may decrease the risk of cardiovascular diseases.
Key words: hyperuricemia, hypertriglyceridemia, dyslipidemia, cardiovascular diseases.